The interconverting phenotypes within patient-derived HER2+/NOTCH1-CTCs and NOTCH inhibitor-sensitive HER2-/NOTCH1+ CTCs contribute to the progression of breast cancer and acquisition of drug resistance. Here, NOTCH1 is linked to breast carcinoma.